Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8537237 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2018 | 25 Pages |
Abstract
Significantly higher values for ODVEN and AM suggest a reduced clearance of ODVEN and active moiety when quetiapine is co-administered. This may be a consequence of a reduced metabolism of venlafaxine to the inactive metabolite N-desmethylvenlafaxine via CYP3A4, the main metabolizing enzyme for quetiapine, and a shift towards a higher proportion of the active metabolite ODVEN. Therapeutic drug monitoring is recommended in the case of co-medication to ensure clinical efficacy and patient safety. Although the increase of AM is moderate, we consider it relevant for clinicians given the prevalence of concomitant medication of quetiapine and venlafaxine.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Michael Paulzen, Georgios Schoretsanitis, Christoph Hiemke, Gerhard Gründer, Ekkehard Haen, Marc Augustin,